Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
Chlormethine
Helsinn Birex Pharmaceuticals Ltd.
L01AA05
chlormethine
Antineoplastic agents
Mycosis Fungoides
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Revision: 9
Authorised
2017-03-03
21 B. PACKAGE LEAFLET 22 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LEDAGA 160 MICROGRAMS/G GEL chlormethine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ledaga is and what it is used for 2. What you need to know before you use Ledaga 3. How to use Ledaga 4. Possible side effects 5. How to store Ledaga 6. Contents of the pack and other information 1. WHAT LEDAGA IS AND WHAT IT IS USED FOR Ledaga contains the active substance chlormethine. This is an anti-cancer medicine used on the skin to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL). MF-type CTCL is a condition in which certain cells of the body’s immune system called T-lymphocytes become cancerous and affect the skin. Chlormethine is a type of anti-cancer medicine called an ‘alkylating agent’. It attaches to the DNA of dividing cells, like cancer cells, which stops them from multiplying and growing. Ledaga is for use in adults only. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE LEDAGA DO NOT USE LEDAGA - if you are allergic (hypersensitive) to chlormethine or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before using Ledaga. - Contact with your eyes must be avoided. Do not apply the medicine near the eyes, to the inside of the nostrils, the inside of the ear or on the lips. - If Ledaga gets in your eyes, it can cause pain, burning, swelling, redness, sensitivity to light, and blurred vision. It may also cause blindness and severe perm Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Ledaga 160 micrograms/g gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of gel contains chlormethine hydrochloride equivalent to 160 micrograms of chlormethine. Excipients with known effect Each tube contains 10.5 grams of propylene glycol and 6 micrograms of butylhydroxytoluene. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Gel. Clear, colourless gel. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Ledaga should be initiated by an appropriately experienced physician. Posology A thin film of Ledaga should be applied once daily to affected areas of the skin. Treatment with Ledaga should be stopped for any grade of skin ulceration or blistering, or moderately severe or severe dermatitis (e.g., marked skin redness with oedema). Upon improvement, treatment with Ledaga can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least 1 week, the frequency of application can be increased to every other day for at least 1 week and then to once-daily application if tolerated. _Elderly_ The dosing recommendation for elderly patients ( 65 years old) is the same as for younger adult patients (see section 4.8). _Paediatric population_ The safety and efficacy of Ledaga in children aged 0 to 18 years have not been established. No data are available. 3 Method of administration Ledaga is for topical application to the skin. The following instructions should be followed by patients or caregivers when applying Ledaga: • Patients must wash hands thoroughly with soap and water immediately after handling or applying Ledaga. Patients should apply Ledaga to affected areas of the skin. In case of Ledaga exposure to non-affected areas of the skin, patients s Lesen Sie das vollständige Dokument